Literature DB >> 25410364

Endogenous and synthetic MMP inhibitors in CNS physiopathology.

Kévin Baranger1, Santiago Rivera2, Fabian D Liechti3, Denis Grandgirard3, Judit Bigas4, Jesús Seco4, Teresa Tarrago5, Stephen L Leib6, Michel Khrestchatisky7.   

Abstract

Matrix metalloproteinases (MMPs, including the membrane-type MMPs (MT-MMPs)), a disintegrin and metalloproteinase (ADAM), and ADAM with thrombospondin motifs belong to the metzincins, a subclass of metalloproteinases that contain a Met residue and a Zn(2+) ion at the catalytic site necessary for enzymatic reaction. MMP proteolytic activity is mainly controlled by their natural tissue inhibitors of metalloproteinase (TIMP). A number of synthetic inhibitors have been developed to control deleterious MMP activity. The roles of MMPs and some of their ECM substrates in CNS physiology and pathology are covered by other chapters of the present volume and will thus not be addressed in depth. This chapter will focus (i) on the endogenous MMP inhibitors in the CNS, (ii) on MMP and TIMP regulations in three large classes of neuropathologic processes (inflammatory, neurodegenerative, and infectious), and (iii) on synthetic inhibitors of MMPs and the perspective of their use in different brain diseases.

Entities:  

Keywords:  Alzheimer's disease; EAE; Synthetic MMP inhibitors; bacterial meningitis; multiple sclerosis

Mesh:

Substances:

Year:  2014        PMID: 25410364     DOI: 10.1016/B978-0-444-63486-3.00014-1

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  18 in total

Review 1.  Demystifying the extracellular matrix and its proteolytic remodeling in the brain: structural and functional insights.

Authors:  Venkat Raghavan Krishnaswamy; Amit Benbenishty; Pablo Blinder; Irit Sagi
Journal:  Cell Mol Life Sci       Date:  2019-06-13       Impact factor: 9.261

Review 2.  Metalloproteinases and their tissue inhibitors in Alzheimer's disease and other neurodegenerative disorders.

Authors:  Santiago Rivera; Laura García-González; Michel Khrestchatisky; Kévin Baranger
Journal:  Cell Mol Life Sci       Date:  2019-06-13       Impact factor: 9.261

3.  Detection of Matrix Metalloproteinases by Zymography.

Authors:  Rajeev B Tajhya; Rutvik S Patel; Christine Beeton
Journal:  Methods Mol Biol       Date:  2017

Review 4.  Laminin as a Biomarker of Blood-Brain Barrier Disruption under Neuroinflammation: A Systematic Review.

Authors:  Juan F Zapata-Acevedo; Valentina García-Pérez; Ricardo Cabezas-Pérez; Monica Losada-Barragán; Karina Vargas-Sánchez; Rodrigo E González-Reyes
Journal:  Int J Mol Sci       Date:  2022-06-17       Impact factor: 6.208

5.  Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation.

Authors:  Robert H Scannevin; Richard Alexander; Tara Mezzasalma Haarlander; Sharon L Burke; Monica Singer; Cuifen Huo; Yue-Mei Zhang; Diane Maguire; John Spurlino; Ingrid Deckman; Karen I Carroll; Frank Lewandowski; Eric Devine; Keli Dzordzorme; Brett Tounge; Cindy Milligan; Shariff Bayoumy; Robyn Williams; Celine Schalk-Hihi; Kristi Leonard; Paul Jackson; Matthew Todd; Lawrence C Kuo; Kenneth J Rhodes
Journal:  J Biol Chem       Date:  2017-08-31       Impact factor: 5.157

6.  The matrix metalloproteinase inhibitor IPR-179 has antiseizure and antiepileptogenic effects.

Authors:  Diede Wm Broekaart; Alexandra Bertran; Shaobo Jia; Anatoly Korotkov; Oleg Senkov; Anika Bongaarts; James D Mills; Jasper J Anink; Jesús Seco; Johannes C Baayen; Sander Idema; Elodie Chabrol; Albert J Becker; Wytse J Wadman; Teresa Tarragó; Jan A Gorter; Eleonora Aronica; Roger Prades; Alexander Dityatev; Erwin A van Vliet
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

7.  The matrix metalloproteinase inhibitor RS-130830 attenuates brain injury in experimental pneumococcal meningitis.

Authors:  Fabian D Liechti; Fabian Bächtold; Denis Grandgirard; David Leppert; Stephen L Leib
Journal:  J Neuroinflammation       Date:  2015-03-04       Impact factor: 8.322

8.  MT5-MMP is a new pro-amyloidogenic proteinase that promotes amyloid pathology and cognitive decline in a transgenic mouse model of Alzheimer's disease.

Authors:  Kévin Baranger; Yannick Marchalant; Amandine E Bonnet; Nadine Crouzin; Alex Carrete; Jean-Michel Paumier; Nathalie A Py; Anne Bernard; Charlotte Bauer; Eliane Charrat; Katrin Moschke; Mothoharu Seiki; Michel Vignes; Stefan F Lichtenthaler; Frédéric Checler; Michel Khrestchatisky; Santiago Rivera
Journal:  Cell Mol Life Sci       Date:  2015-07-23       Impact factor: 9.261

9.  Surgery-Induced Hippocampal Angiotensin II Elevation Causes Blood-Brain Barrier Disruption via MMP/TIMP in Aged Rats.

Authors:  Zhengqian Li; Na Mo; Lunxu Li; Yiyun Cao; Wenming Wang; Yaoxian Liang; Hui Deng; Rui Xing; Lin Yang; Cheng Ni; Dehua Chui; Xiangyang Guo
Journal:  Front Cell Neurosci       Date:  2016-04-26       Impact factor: 5.505

10.  MT5-MMP, just a new APP processing proteinase in Alzheimer's disease?

Authors:  Kévin Baranger; Michel Khrestchatisky; Santiago Rivera
Journal:  J Neuroinflammation       Date:  2016-06-28       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.